Timothy Brown, MD
Medical Oncology · Dallas, TXNPI 1790171239
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $12,650 of the $20,110 with a category attached, or 62.9%. Incyte Corporation accounts for 89.3% of it on its own, with 13 other manufacturers making up the rest. 2025 is the largest year on record at $19,555, more than ten times the $108 reported in 2020.
Across 44 payments — averaging $457.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$18K
- Daiichi Sankyo Inc.$1K
- AstraZeneca$211
- Astellas Pharma US Inc$120
- Heron Therapeutics, Inc.$119
- Johnson & Johnson$83
- plus $265 from 8 others
Across 9 payments — averaging $12,325 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Modernatx, Inc.$70K
- Kyowa Kirin Co., Ltd$41K
What the payments were for
- Consulting fees$4,38022%
- Speaking & faculty fees$12,65063%
- Travel & lodging$1,6688%
- Food & beverage$1,4127%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Incyte Corporation | 25 | $17,956 |
| Daiichi Sankyo Inc. | 1 | $1,355 |
| AstraZeneca | 2 | $211 |
| Astellas Pharma US Inc | 5 | $120 |
| Heron Therapeutics, Inc. | 1 | $119 |
| Johnson & Johnson | 1 | $83 |
| Zimmer Biomet | 1 | $64 |
| Janssen Research & Development, LLC | 1 | $57 |
| Exelixis Inc. | 2 | $38 |
| AVEO Pharmaceuticals, Inc. | 1 | $28 |
| Geron Corporation | 1 | $25 |
| Merck | 1 | $20 |
| Emmaus Medical, Inc. | 1 | $17 |
| Smith+Nephew | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$20,110 in reported general payments places this provider in the 70th percentile of 495 medical oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Imatinib Mesylate | 13 | $878 |
| Prochlorperazine Maleate | 41 | $383 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 15 | $299 |
| Dexamethasone | 27 | $281 |
| Ondansetron Hcl | 49 | $230 |
| LoperamideLoperamide Hcl | 12 | $199 |
| Furosemide | 11 | $26 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Dallas
- Moshe LevyDallas$5.1M
- Andrew WhiteleyDallas$1.7M
- Eric NadlerDallas$1.6M
- Joyce O'ShaughnessyDallas$1.3M
- Ronan KellyDallas$1.1M
- Thomas HutsonDallas$944K
- Heather McArthurDallas$314K
- Tian ZhangDallas$286K
- Micah BurchDallas$221K
- David JohnsonDallas$212K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.